麻豆传媒

As Professor of Medicine and Urology at Yale School of Medicine, Dr. Daniel P. Petrylak is a pioneer in the research and development of new drugs and treatments to fight prostate, bladder, kidney and testicular cancer. For patients fighting these types of cancers, Petrylak finds recent developments in the field of immunotherapy particularly promising. “Up until recently, bladder cancer had not seen any major advancement in more than 30 years,” he says. “Studies are ongoing, but interim results are exciting so far.”
At the Smilow Cancer Hospital, Dr. Petrylak’s position as a national leader on clinical trials for men with prostate and bladder cancer has opened up a world of treatment options for patients in New England. “We offer the latest investigational drugs for these conditions, while providing the highest level of care,” he says.
Dr. Petrylak received his MD from Case Western Reserve University School of Medicine and joined the Yale faculty in 2012. In addition to his role as professor, he is also a member of the Cancer Signaling Networks Research Program at Yale Cancer Center, which studies how cancer stem cells are regulated in the body and communicate with surrounding tissue. Roughly 40 physicians and scientists in the program work together to develop the best methods for matching patients with the appropriate cancer drugs.
One of Dr. Petrylak’s key goals is to continue to successfully translate basic research into clinical practice. “One of the most significant accomplishments in my career was moving docetaxel (an antineoplastic agent) therapy for the most advanced form of prostate cancer from phase I to III,” he says. “We ran a trial which supported its approval for the most advanced form of prostate cancer.”
Dr. Petrylak currently serves as either the principal investigator or co-principal investigator on seven Southwest Oncology Group (SWOG) clinical trials for genitourinary cancers. To date, he has authored more than 100 peer-reviewed articles on prostate and bladder cancer research.

Hospital resident at Yale School of Medicine

Lajos Pusztai, MD, DPhil, is a medical oncologist who specializes in breast cancer. He is the co-director of the Genomics, Genetics, and Epigenetics Program at the Yale Cancer Center.
He says he enjoys the delicate work of helping patients overcome the fear and shock of a breast cancer diagnosis. “I ensure that they maximize their chance of cure through the best available treatments,” he says. “I also love the research component of my job, to push the boundaries of existing knowledge and developing new therapies.”
Dr. Pusztai says he gravitated to medical oncology at the beginning of his career because of an inspiring mentor, and that the best part of his job is seeing patients remain disease-free for years and continuing with their life.
He is chair of the Breast Cancer Research Committee of the South West Oncology Group (SWOG), a global cancer research community that designs and conducts publicly funded clinical trials. His research group has made important contributions to establish that estrogen receptor-positive and-negative breast cancers have fundamentally different molecular, clinical, and epidemiological characteristics.
He has been a pioneer in evaluating gene expression profiling as a diagnostic technology to predict chemotherapy and endocrine therapy sensitivity and has shown that different biological processes are involved in determining the prognosis and treatment response in different breast cancer subtypes. Dr. Pusztai is also the principal investigator of several clinical trials investigating new drugs, including immunotherapies for breast cancer.

Shail Maingi, MD (she/her) is a medical oncologist, hematologist, and palliative care physician at the Dana-Farber Cancer Institute South Shore location. In addition to seeing patients with solid tumors and blood diseases, she is the inaugural DFCI Network Health Equity and Inclusion Liaison. Dr. Maingi has been a health equity advocate and clinical researcher for years, with a focus on health care disparities in oncology and end-of-life settings, particularly for sexual and gender minority people and with a focus on intersectionality.  She is currently part of the scientific program committee for the American Society of Clinical Oncology (ASCO) annual conference and serves on ASCO’s Diversity and Inclusion Committee, Practice Health Task Force, and as the co-chair of their Sexual and Gender Minority Task Force. Dr. Maingi was also the founding chair of the American Academy of Hospice and Palliative Medicine’s LGBTQ Special Interest Group. She serves on the GLMA: Health Professionals Advancing LGBTQ Equality board and heads their Racial Justice Task Force, after serving as their VP for the Lesbian Health Fund for 6 years. 

Dr. Kimia Sorouri is a clinician-researcher with an interest in fertility, particularly fertility preservation and ovarian toxicity of anti-cancer drugs and novel therapeutics. She is currently a senior resident physician in Obstetrics & Gynecology at the Lois Hole Hospital for Women, one of the highest-volume sites in Canada, and concurrently appointed as a research fellow at Dana-Farber Cancer Institute/ Harvard Medical School. 

She received her MD from the University of Toronto and her MPH from Harvard University as a Frank Knox Memorial Fellow. She then completed her postdoctoral fellowship at Dana-Farber Cancer Institute/ Harvard Medical School with Dr. Ann H. Partridge researching the reproductive health of cancer patients and survivors. In addition, she has an interest in leveraging technology to advance women’s health through her involvement with early-stage companies as an advisor and founder.

Dr. Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. He is the Medical Director, International Strategic Initiatives at Dana-Farber and past President of the Medical Staff at DFCI (2016-2018). He received the George Canellos Award for Excellence in Clinical Investigation and Patient Care from DFCI in 2013, the Eugene Schonfeld Award from the Kidney Cancer Association (KCA) in 2016, and is a 2021 Giants of Cancer Care inductee. He serves on the National Comprehensive Cancer Network (NCCN) Kidney Cancer Panel, KidneyCan Board, the National Cancer Institute (NCI) GU Steering Committee, and is past Chairman (2015-2018) of the Medical and Scientific Steering Committee of the KCA. Dr. Choueiri is an elected member of the American Society of Clinical Investigation (ASCI). In addition, he is an Aresty Scholar from the Wharton School of Business at the University of Pennsylvania.
Dr. Choueiri is interested in developing novel experimental therapies and biomarkers in GU malignancies, including renal cell carcinoma (RCC). In a series of New England Journal of Medicine (NEJM) articles on which he was either first or senior author, Dr. Choueiri and colleagues have made seminal observations that have defined and evolved the treatment of metastatic RCC and led to the approval of several therapies such as Cabozantinib, Pazopanib, Avelumab+Axitinib, Cabozantinib+Nivolumab, and Pembrolizumab+Lenvatinib, as well as adjuvant pembrolizumab. His research also focuses on the epidemiology, diagnosis, and treatment outcomes of GU cancers, especially through having co-established the International Metastatic RCC Database Consortium criteria for RCC risk stratification. His biomarker work has shed light on complex immunogenomics mechanisms contributing to response and resistance to targeted therapy and immunotherapy. He has also contributed to our understanding of the underlying biology and rationale for therapies in rare histological variants of RCC such as papillary, translocation, and sarcomatoid RCC.
Dr. Choueiri has received research funding from the NCI, the Department of Defense (DOD), the American Society of Clinical Oncology (ASCO), and industry partners. His work has been published in journals such as the NEJM, Nature, Nature Medicine, Science, Cancer Cell, Journal of American Medical Association (JAMA), JAMA Oncology, The Lancet, Lancet Oncology, and Journal of Clinical Oncology. He lectures frequently throughout the United States and around the world. He has over 675 PubMed-indexed publications and is the lead investigator of multiple national and international phase I-III trials in GU cancers.

Dr. Narjust Florez is the Associate Director of the Cancer Care Equity Program and a thoracic medical oncologist at the Dana-Farber Brigham Cancer Center. She completed her internal medicine residency in Rutgers New Jersey Medical School and fellowship at the Mayo Clinic in Rochester, Minnesota where she was the chief fellow from 2018-2019.
Dr. Florez's clinical interests include targeted therapy for lung cancer and the care of women with lung cancer, including their unique aspects of cancer survivorship. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer.
Apart from her clinical interests in lung cancer, she is also a leading and productive researcher in cancer health disparities, gender and racial discrimination in medical education and medicine. She received many awards including the 2018 Resident of the Year Award by the National Hispanic Medical Association, the Mayo Brothers Distinguished Fellowship award and the 2020 Rising Star award by the LEAD national conference for women in hematology and oncology.
In addition, Dr. Florez founded the Florez Lab in 2019. The laboratory focuses on lung cancer, social justice issues in medicine and medical education. The laboratory long-term goals are to create a welcoming environment for medical trainees from historically underrepresented groups in medicine while improving the care of vulnerable populations. Members of the Florez Lab are agents of change.

Dr. Rachel Freedman is a medical oncologist and clinical researcher at DFCI in the Breast Oncology Program.  In addition to seeing patients with breast cancer, her research focuses on improving the care of vulnerable patient populations who are under-represented in clinical trials and who are at risk for worse breast cancer outcomes, including older women and those who face challenges in access to care.  In addition, she is interested in novel therapeutics, serving as the Principal Investigator for several clinical trials.  She is also the founder and Director of the Program for Older Adults with Breast Cancer at DFCI.  Dr. Freedman joined the faculty at DFCI in 2009.  She studied at Georgetown University School of Medicine and obtained her master's in public health at the Harvard University T.H. Chan School of Public Health.  Her research has been funded by Susan G Komen, ACS, NCI, Gateway for Cancer Research, METAvivor, and the Alliance for Clinical Trials Foundation.

Dr. Garrido-Castro is a medical oncologist specialized in breast cancer at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School.  Since joining the Breast Oncology Center at Dana-Farber in 2016, Dr. Garrido-Castro has established an active clinical practice and research efforts focused on the development of novel therapies to improve outcomes in patients with breast cancer.  Dr. Garrido-Castro is Co-Director of the Triple-Negative Breast Cancer (TNBC) Working Group at Dana-Farber and leads clinical trials studying immunotherapy and targeted therapy approaches for patients with breast cancer.

Dr. Tolaney received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital, where she serves as Chief of the Division of Breast Oncology.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy. 




 

Gilbert Youssef, MD is Neuro-Oncologist at Dana-Farber Cancer Institute.  He primarily treats patients with brain and spinal cord tumors, including, glioma, meningioma, ependymoma, medulloblastoma, schwannoma, lymphoma, and brain metastases.  He also treats patients who develop neurologic complications from cancer or its treatment.
He is interested in neuroimaging, while focusing on clinical endpoints in clinical trials.  He is also involved in multiple clinical trials that are ongoing at Dana-Farber.

Dr. Wen graduated from the Medical College of St. Bartholomew's Hospital, University of London, in 1981. He completed his internal medicine training at the University of London postgraduate hospitals and his neurology residency in the Harvard-Longwood Neurology Training Program. His research is focused on novel treatments of brain tumors, especially targeted molecular agents. His other clinical interests include neurologic complications of cancer.




 

Dr. Kehl received his MD from the Feinberg School of Medicine at Northwestern University in 2008. He completed his residency in internal medicine at the Brigham and Women’s Hospital. He received his fellowship training in hematology and medical oncology at the MD Anderson Cancer Center and joined the faculty in the Lowe Center for Thoracic Oncology and the Division of Population Sciences at Dana-Farber in 2017. His research focuses on the impact of healthcare delivery strategies on access to care and outcomes for patients with lung cancer, with a particular focus on analysis of population-level data.




 

Dr. Manz graduated from Duke University School of Medicine in 2012. He received his training in internal medicine at the Hospital of the University of Pennsylvania from 2012-2015, and subsequently worked as a hospitalist in oncology at the same hospital until 2017. After completing fellowship in hematology/oncology and a Masters of Science in Health Policy Research at the University of Pennsylvania, he joined Dana-Farber in GI Oncology and the Department of Population Sciences 2020.

Dr. Jänne received his MD and PhD from the University of Pennsylvania in 1996. He completed postgraduate training in internal medicine at Brigham and Women's Hospital and in medical oncology at DFCI in 2001. He is the Senior Vice President for Translational Medicine and the Scientific Director of the Belfer Center for Applied Cancer Science. His main research interests include studying the therapeutic relevance of oncogenic alterations in lung cancer. He was one of the co-discoverers of epidermal growth factor receptor (EGFR) mutations and has led the development of therapeutic strategies for patients with EGFR mutant lung cancer.




 

Dr. Shulman studies novel therapies and biomarkers for patients with advanced sarcomas. In addition to early phase clinical trials, Dr. Shulman co-leads an effort to evaluate circulating tumor DNA, a type of "liquid biopsy," as a potential tool to improve the ways in which we treat patients with bone and soft tissue sarcomas.




 

Church is a board-certified Pediatric Pathologist and Molecular Genetic Pathologist. She is the Associate Director of the Laboratory for Molecular Pediatric Pathology (LaMPP) at Boston Children’s Hospital, and an Assistant Professor at Harvard Medical School.? She has participated in several high-impact studies using molecular profiling for pediatric cancers, including the?iCat?study, Profile study, and the ongoing multi-institutional GAIN consortium study and Broad Institute's Count Me In study.? Her career is dedicated to implementing high-quality accessible molecular profiling tests to support the care of children with cancer.

Dr. Marron received his medical degree from the David Geffen School of Medicine at UCLA in 2008. He completed his residency in Pediatrics at Stanford University and his fellowship in Clinical Medical Ethics at the University of Chicago followed by his fellowship in Pediatric Hematology/Oncology at Boston Children's Hospital and the Dana-Farber Cancer Institute. Dr. Marron also received an MPH in 2016 from the Harvard T.H. Chan School of Public Health. Jonathan cares for pediatric oncology patients in the inpatient setting at Boston Children's Hospital and in the outpatient clinic at the Dana-Farber Cancer Institute. His research interests are in ethics and decision-making, health services, clinical genomics, informed consent, and medical uncertainty. Much of Dr. Marron's current work focuses on patient, parent and physician decision-making regarding pediatric precision cancer medicine. He also teaches medical ethics to medical students and graduate students through his role as teaching faculty at the Harvard Medical School Center for Bioethics.

Dr. Gillani uses computational techniques to understand the markers in cancer and normal patient genomes that are associated with the development and progression of disease, leveraging these insights to inform novel approaches to the treatment of pediatric cancer. He cares for patients with a range of solid tumor and hematologic malignancy diagnoses, with the overall aim of translating research insights to improved patient management.




 

The diagnosis of cancer is incredibly difficult for anyone, but when it’s your child, it’s particularly devastating. I make sure to reassure patients, parents, families and caregivers that this is a partnership and a journey we will weather together. Part of my job is to teach them about the tumor, the treatment, and expected side effects of that treatment, but what they don’t initially realize is how much they will teach me in return. I’ve had years of training to prepare for this; they have had but a few weeks. Yet one of the most rewarding parts of my job is to watch my patients, their families and caregivers transition from students to teachers. I think it’s important to also acknowledge that although we may not cure every patient with a brain tumor, we will help patients to live as long and as well as possible with current therapies and supportive care.